-
Study aim
-
To determine the effect of doxycycline in chronic rhinosinusitis with nasal polyps
-
Design
-
A clinical trial study with control group, parallel groups, double-blinded, randomized with block randomization, phase 3 on 90 patients.
-
Settings and conduct
-
This study is performed on 90 patients in Hazrat Rasool Hospital. Patients are randomly divided into intervention group and control group. Blindnig will be performed on patients, researcher, and outcome assessor. Patients are assessed for quality of life, symptoms severity, peak nasal inspiratory flow, total serum IgE, peripheral eosinophil count, nasal mucosal eosinophil count and nasal polyp size.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: Patients with chronic rhinosinusitis with nasal polyps who have moderate to severe disease and are 18 to 60 years old;
Exclusion criteria: Pregnancy, Breast feeding, sinus surgery within the last 3 months, antibiotic consumption within the last month, History of allergic reaction to doxycycline, renal failure or liver failure, Warfarin consumption.
-
Intervention groups
-
Intervention group: Nasal fluticasone spray, Montelukast and nasal irrigation as baseline treatment and oral enteric coated doxycycline (Behshad Darou, Iran) 200 Mg on day 1 then 100 Mg daily for 6 weeks.
Control group: Nasal fluticasone spray, Montelukast and nasal irrigation as baseline treatment and placebo two capsules on day 1 then one capsule daily for 6 weeks.
-
Main outcome variables
-
Quality of life based on Sino-Nasal Outcome Test 22 (SNOT22),
symptoms severity, peak nasal inspiratory flow and nasal polyp size